The Correlation Of Visfatin, Mmp-9 And Insulin Resistance In Patients With Coronary Heart Disease

Background: This study was aimed to determine the association between serum levels of visfatin and matrix metallopeptidase 9 (MMP-9) and homeostasis model assessment-insulin resistance (HOMA-IR) in patients with coronary heart disease (CHD). Materials and methods: During November 2009 and March 2011, CHD patients and non-CHD patients (controls) receiving coronary arteriography were selected. Eligible CHD patients were classified into two groups of CHD with insulin resistance (IR) and CHD without IR. The serum biochemical indexes including the levels of visfatin and MMP-9 in CHD patients and the cut-off values of them for CHD with IR were measured. Results: Total 32 CHD patients with IR (12 male, 20 female), 28 CHD patients without IR (11 male, 17 female) and 20 control patients (12 male, 35 female) were enrolled. The serum concentration of visfatin and MMP-9 among control group, CHD without IR group and CHD with IR group were significantly different (P < 0.05 for all). In patients with CHD, the HOMA-IR and Gensini's score were both positively correlated with serum levels of visfatin (r = 0.5549, P < 0.01; r = 0.6231, P < 0.01) and MMP-9 (r = 0.4211, P < 0.01; r = 0.6179, P < 0.01). Furthermore, there was a positive correlation between visfatin and MMP-9 (r = 0.6377, P < 0.01), as well as between Gensini's score and HOMA-IR (r = 0.5023, P < 0.01). The cut-off values of visfatin and MMP-9 were 40.25 ng/ml and 443.21 ng/ml, respectively. Conclusions: HOMA-IR may be a risk factor for CHD. Serum concentrations of visfatin and MMP-9 could be positive correlated with CHD and HOMA-IR.